518 related articles for article (PubMed ID: 17174640)
1. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
2. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
4. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
5. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
7. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
[TBL] [Abstract][Full Text] [Related]
8. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Wallentin L; Varenhorst C; James S; Erlinge D; Braun OO; Jakubowski JA; Sugidachi A; Winters KJ; Siegbahn A
Eur Heart J; 2008 Jan; 29(1):21-30. PubMed ID: 18055486
[TBL] [Abstract][Full Text] [Related]
11. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Payne CD; Weerakkody GJ; Li YG; Brandt JT; Salazar DE; Winters KJ
J Clin Pharmacol; 2008 Apr; 48(4):475-84. PubMed ID: 18303127
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Jernberg T; Payne CD; Winters KJ; Darstein C; Brandt JT; Jakubowski JA; Naganuma H; Siegbahn A; Wallentin L
Eur Heart J; 2006 May; 27(10):1166-73. PubMed ID: 16621870
[TBL] [Abstract][Full Text] [Related]
13. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
Weerakkody GJ; Jakubowski JA; Brandt JT; Farid NA; Payne CD; Zhu J; Warner MR; Naganuma H; Winters KJ
Am J Cardiol; 2007 Jul; 100(2):331-6. PubMed ID: 17631093
[TBL] [Abstract][Full Text] [Related]
14. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Payne CD; Li YG; Brandt JT; Jakubowski JA; Small DS; Farid NA; Salazar DE; Winters KJ
Platelets; 2008 Jun; 19(4):275-81. PubMed ID: 18569863
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
[TBL] [Abstract][Full Text] [Related]
16. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
[TBL] [Abstract][Full Text] [Related]
19. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
[TBL] [Abstract][Full Text] [Related]
20. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Zhu B; Effron MB; Kulkarni MP; Li YG; Jakubowski JA; Miller DL; Baker BA; Luo J; Small DS; Winters KJ
J Cardiovasc Pharmacol; 2011 Mar; 57(3):317-24. PubMed ID: 21266916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
